HomeCompareINFI vs JEPI

INFI vs JEPI: Dividend Comparison 2026

INFI yields 25000.00% · JEPI yields 8.40%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 INFI wins by $481652020747103174656.00M in total portfolio value
10 years
INFI
INFI
● Live price
25000.00%
Share price
$0.01
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$481652020747103174656.00M
Annual income
$477,891,679,681,809,340,000,000,000.00
Full INFI calculator →
JEPI
JPMorgan Equity Premium Income ETF
● Live price
8.40%
Share price
$56.68
Annual div
$4.76
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$29.0K
Annual income
$1,528.62
Full JEPI calculator →

Portfolio growth — INFI vs JEPI

📍 INFI pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodINFIJEPI
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, INFI + JEPI cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
INFI pays
JEPI pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

INFI
Annual income on $10K today (after 15% tax)
$2,125,000.00/yr
After 10yr DRIP, annual income (after tax)
$406,207,927,729,537,960,000,000,000.00/yr
JEPI
Annual income on $10K today (after 15% tax)
$714.16/yr
After 10yr DRIP, annual income (after tax)
$1,299.33/yr
At 15% tax rate, INFI beats the other by $406,207,927,729,537,960,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of INFI + JEPI for your $10,000?

INFI: 50%JEPI: 50%
100% JEPI50/50100% INFI
Portfolio after 10yr
$240826010373551587328.00M
Annual income
$238,945,839,840,904,670,000,000,000.00/yr
Blended yield
99.22%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on INFI right now

INFI
Analyst Ratings
8
Buy
9
Hold
Consensus: Hold
Altman Z
-63.6
Piotroski
3/9
JEPI
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

INFI buys
0
JEPI buys
0
No recent congressional trades found for INFI or JEPI in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricINFIJEPI
Forward yield25000.00%8.40%
Annual dividend / share$2.00$4.76
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$481652020747103174656.00M$29.0K
Annual income after 10y$477,891,679,681,809,340,000,000,000.00$1,528.62
Total dividends collected$481404327977371041792.00M$11.7K
Payment frequencyquarterlymonthly
SectorStockETF

Year-by-year: INFI vs JEPI ($10,000, DRIP)

YearINFI PortfolioINFI Income/yrJEPI PortfolioJEPI Income/yrGap
1← crossover$2,510,700$2,500,000.00$11,260$840.19+$2.50MINFI
2$589,298,599$586,612,149.53$12,641$907.94+$589.29MINFI
3$129,309,604,119$128,679,054,618.90$14,150$978.20+$129309.59MINFI
4$26,527,150,102,459$26,388,788,826,051.22$15,795$1,050.85+$26527150.09MINFI
5$5,087,743,001,217,608$5,059,358,950,607,977.00$17,584$1,125.74+$5087743001.20MINFI
6$912,316,496,169,531,500$906,872,611,158,228,600.00$19,526$1,202.74+$912316496169.51MINFI
7$152,954,929,371,424,950,000$151,978,750,720,523,570,000.00$21,628$1,281.69+$152954929371424.91MINFI
8$23,976,822,470,935,107,000,000$23,813,160,696,507,682,000,000.00$23,898$1,362.43+$23976822470935108.00MINFI
9$3,514,337,444,199,857,700,000,000$3,488,682,244,155,957,000,000,000.00$26,347$1,444.79+$3514337444199857664.00MINFI
10$481,652,020,747,103,200,000,000,000$477,891,679,681,809,340,000,000,000.00$28,982$1,528.62+$481652020747103174656.00MINFI

INFI vs JEPI: Complete Analysis 2026

INFIStock

Infinity Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel medicines for people with cancer. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 2 clinical trials for the treatment of metastatic triple negative breast cancer and urothelial cancer; and Phase 1/1b clinical trials for the treatment of solid tumors. The company has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib; and PellePharm, Inc. to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate, as well as collaboration agreements with Arcus Biosciences, Inc., F. Hoffmann-La Roche Ltd., and Bristol Myers Squibb Company. Infinity Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Cambridge, Massachusetts.

Full INFI Calculator →

JEPIETF

The fund seeks to provide the majority of the returns associated with its primary benchmark, the Standard & Poor's 500 Total Return Index (S&P 500 Index), while exposing investors to less risk through lower volatility and still offering incremental income. Under normal circumstances, the fund invests at least 80% of its assets in equity securities. It may also invest in other equity securities not included in the S&P 500 Index.

Full JEPI Calculator →
📬

Get this INFI vs JEPI comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

INFI vs SCHDINFI vs OINFI vs KOINFI vs MAININFI vs JEPQINFI vs XYLDINFI vs DIVOINFI vs QYLD

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.